Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: Analysis of subgroups based on new risk criteria

Multiple Sclerosis

Volumn 15, Issue 6, 2009, Pages 728-734

  O'Connor, Paul ^a   Kinkel, R P ^b   Kremenchutzky, M ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Clinically definite multiple sclerosis; Clinically isolated syndrome; Intramuscular interferon beta 1a

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; METHYLPREDNISOLONE; PLACEBO; PREDNISONE;

ADULT; ALGORITHM; ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CLINICALLY ISOLATED SYNDROME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; IMAGE ENHANCEMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SYMPTOMATOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALGORITHMS; BRAIN; DISEASE PROGRESSION; FEMALE; GADOLINIUM; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 66149163115     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509103173     Document Type: Article

References (20)

1. Miller, D, Barkhof, F, Montalban, X, Thompson, A, Filippi, M. Clinically isolated syndromes suggestive of multiple sclerosis, part 1: Natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4: 281-288.
2. Frohman, EM, Goodin, DS, Calabresi, PA, et al. The utility of MRI in suspected MS. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 602-611.
3. IFNB Multiple Sclerosis Study Group. Interferon beta-1a is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
4. Jacobs, LD, Cookfair, DL, Rudick, RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-294.
5. PRISMS. (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
6. PRISMS. (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636.
7. Jacobs, LD, Beck, RW, Simon, JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
8. The CHAMPIONS Study Group. IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678-684.
9. Beck, RW, Chandler, DL, Cole, SR, et al. Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002; 51: 481-490.
10. McDonald, WI, Compston, A, Edan, G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
11. Uitdehaag, BMJ, Kappos, L, Bauer, L, et al. Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Mult Scler 2005; 11: 227-231.
12. Kappos, L, Polman, CH, Freedman, MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 944-953.
13. Zipoli, V, Portaccio, E, Siracusa, G, et al. Interobserver agreement on Poser's and the new McDonald's diagnostic criteria for multiple sclerosis. Mult Scler 2003; 9: 481-485.
14. Comi, G, Filippi, M, Barkhof, F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 2001; 357: 1576-1582.
15. Poser, CM, Paty, DW, Scheinberg, L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
16. The CHAMPS Study Group. Predictors of short-term disease activity following a first clinical demyelinating event: Analysis of the CHAMPS placebo group. Mult Scler 2002; 8: 405-409.
17. O'Connor, P. The effects of intramuscular interferon beta-1a in patients at high risk for development of multiple sclerosis: A post hoc analysis of data from CHAMPS. Clin Ther 2003; 25: 2865-2874.
18. O'Connor, PW, Miller, D, Riester, K, et al. Relapse rates and enhancing lesions in a phase II trial of natalizumabin multiple sclerosis. Mult Scler 2005; 11: 568-572.
19. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology 1997; 49: 1404-1413.
20. Polman, CW, Kappos, L, Freedman, MS, et al. Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. J Neurol 2008; 255: 480-487.